CLINICAL TRIALS PROFILE FOR HARVONI

All Clinical Trials for Harvoni

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02339038 ↗	Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia	Completed	National Institutes of Health Clinical Center (CC)	Phase 4	2015-01-07	Background: - Treatment for Hepatitis C has changed a lot in the past 2 years. Most of this change comes from a combination of medicines that is yielding high cure rates. But its long-term effects are uncertain. One problem is that a lot of people need the treatment, but only a few specialists can give it. The success rate for Hepatitis C treatment by primary care doctors, nurse practitioners, or physician assistants is largely unknown. Researchers want to see how provider type affects treatment outcomes. They will conduct a large, community-based study in the District of Columbia. Objectives: - To see if people can be treated for Hepatitis C safely and successfully in community-based health centers. Eligibility: - Adults who need treatment for chronic Hepatitis C infection. Design: - Participants will be screened with blood tests. Their current medicines will be reviewed. - Participants will give researchers access to their medical records. Researchers will follow participants through these records. - Participants will see a primary care or infectious disease provider. The provider will tell them about their treatment. They will be told how often they will visit the provider and how often they will have their blood drawn. They will get a calendar of study visits. - Participants will take Harvoni for 8, 12, or 24 weeks. They will visit their care provider monthly. - Participants will have monthly follow-up visits for up to 3 months after they finish their medicine. - Participants will have yearly follow-up visits with their care provider for up to 10 years.
NCT02347345 ↗	Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs	Completed	National Institute on Drug Abuse (NIDA)	Phase 4	2016-11-15	The investigator's hypothesis is that active injectors will show a partial reduction in markers of immune activation with HCV therapy whereas non-injectors will show a more significant reduction in these markers, and will exhibit levels of immune activation that approach that seen in similarly studied healthy volunteers.This is based on observations that this group of investigators have made. They have shown that individuals who inject drugs have high level of immune activation in blood and tissue. Immune activation or chronic inflammation has been associated with accelerated aging, cardiovascular, renal and liver disease as well as CNS dysfunction. It remains unclear whether increased levels of immune activation are due to non-sterile injection of drugs, chronic infection with Hepatitis C, chronic opiate use, or perhaps combinations of all 3. To understand the potential contribution of infection with Hepatitis C the investigators will compare levels of immune activation pre- and post treatment with an all oral, one pill once daily, interferon sparing treatment of HCV in 2 groups of chronically HCV infected patients- one actively injecting with drugs and the other free of injection for at least 4 months. Immune activation comparisons will also include non-injecting healthy volunteers.
NCT02347345 ↗	Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs	Completed	Rockefeller University	Phase 4	2016-11-15	The investigator's hypothesis is that active injectors will show a partial reduction in markers of immune activation with HCV therapy whereas non-injectors will show a more significant reduction in these markers, and will exhibit levels of immune activation that approach that seen in similarly studied healthy volunteers.This is based on observations that this group of investigators have made. They have shown that individuals who inject drugs have high level of immune activation in blood and tissue. Immune activation or chronic inflammation has been associated with accelerated aging, cardiovascular, renal and liver disease as well as CNS dysfunction. It remains unclear whether increased levels of immune activation are due to non-sterile injection of drugs, chronic infection with Hepatitis C, chronic opiate use, or perhaps combinations of all 3. To understand the potential contribution of infection with Hepatitis C the investigators will compare levels of immune activation pre- and post treatment with an all oral, one pill once daily, interferon sparing treatment of HCV in 2 groups of chronically HCV infected patients- one actively injecting with drugs and the other free of injection for at least 4 months. Immune activation comparisons will also include non-injecting healthy volunteers.
NCT02480166 ↗	Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6	Completed	Gilead Sciences	Phase 4	2015-06-01	The primary objectives of this study are to describe the efficacy of: 1. 8-week treatment of SOF/LED for treatment-naïve, non-cirrhotic, HCV genotype 6 2. 12-week treatment of SOF/LED for all other HCV-6 populations
NCT02480166 ↗	Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6	Completed	Stanford University	Phase 4	2015-06-01	The primary objectives of this study are to describe the efficacy of: 1. 8-week treatment of SOF/LED for treatment-naïve, non-cirrhotic, HCV genotype 6 2. 12-week treatment of SOF/LED for all other HCV-6 populations

Clinical Trial Conditions for Harvoni

Condition Name

Condition Name for Harvoni
Intervention	Trials
Hepatitis C	15
Chronic Hepatitis C	4
Hepatitis C, Chronic	3
Healthy	2

Condition MeSH

Condition MeSH for Harvoni
Intervention	Trials
Hepatitis C	29
Hepatitis	29
Hepatitis A	22
Hepatitis C, Chronic	11

Clinical Trial Locations for Harvoni

Trials by Country

Trials by Country for Harvoni
Location	Trials
United States	62
Italy	6
Egypt	5
Canada	3
Korea, Republic of	2

Trials by US State

Trials by US State for Harvoni
Location	Trials
New York	8
California	7
Texas	5
Pennsylvania	4
Maryland	4

Clinical Trial Progress for Harvoni

Clinical Trial Phase

Clinical Trial Phase for Harvoni
Clinical Trial Phase	Trials
Phase 4	16
Phase 3	3
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for Harvoni
Clinical Trial Phase	Trials
Completed	21
Recruiting	3
Active, not recruiting	3

Clinical Trial Sponsors for Harvoni

Sponsor Name

Sponsor Name for Harvoni
Sponsor	Trials
Gilead Sciences	12
University of Maryland	3
Genuine Research Center, Egypt	2

Sponsor Type

Sponsor Type for Harvoni
Sponsor	Trials
Other	59
Industry	17
NIH	7

Clinical Trials Update, Market Analysis, and Projection for Harvoni

Last updated: January 27, 2026

---

Summary

Harvoni (ledipasvir and sofosbuvir), developed by Gilead Sciences, is a leading oral hepatitis C virus (HCV) treatment launched in 2014. It revolutionized HCV therapy with high cure rates, shorter treatment durations, and improved safety profiles. Despite its clinical success, the drug's market landscape faces evolving competition, patent expirations, generics entry, and ongoing clinical research aimed at expanding indications. This report details recent clinical trial updates, current market status, competitive dynamics, regulatory considerations, and future market projections specific to Harvoni.

---

1. Clinical Trials Update

Recent Clinical Trial Activity

Trial Phase	Focus Areas	Key Studies & Results	Status	Source
Phase II & III	Efficacy in diverse populations	Multiple studies evaluating Harvoni in various genotypes and co-infections	Ongoing / Completed	[1][2]
Post-Market	Real-world effectiveness and safety	Observational studies assessing long-term outcomes	Ongoing	[3]
Expanded Indications	HCV with comorbidities, pediatric use	Trials exploring safety/efficacy in pediatric populations and cirrhotic patients	Active / Pending results	[4][5]

Key Clinical Developments

• Genotype 3 Efficacy: Recent data indicates promising results of Harvoni in genotype 3 infected patients, historically challenging to treat, with sustained virologic response (SVR) rates exceeding 90% in real-world cohorts [2].
• Cirrhotic Patients: Updated data supports Harvoni's use in compensated cirrhotic patients, maintaining high SVR rates (~95%) with a tolerable safety profile.
• Pediatric Trials: Gilead's ongoing studies assessing adolescent safety (ages 12–17), with phase II data showing comparable efficacy and safety to adult populations.

Implications of Clinical Trials

• The expanding evidence base supports expanded labeling and guideline inclusion.
• Negative trial outcomes in specific genotypes or comorbidities could impact prescription patterns.
• Real-world data continues to reinforce Harvoni’s standing but highlights the importance of optimizing patient selection.

---

2. Market Analysis

Market Size and Penetration

Parameter	Figures / Status	Notes
Global HCV market (2022)	~$6.5 billion[6]	Estimated permanent market impact, with significant regional variation
Harvoni's market share 2014-2022	Peak ~40%, declining to ~20% in 2022 due to new entrants and generics	Dominant since launch; erosion mainly driven by generics in certain regions
Key geographical markets	U.S., Europe, Japan, emerging markets	U.S. remains the largest, followed by Europe; growth in Asia-Pacific regions varies

Patent Status and Generic Competition

Patent Expiration / Patent Challenges	Dates / Status	Impact on Market	Source
Original Patent (Harvoni)	2025 (expected)	Approaching expiration, increasing generic access	[7]
Patent challenges in India	2022–2024	Significant generic penetration anticipated	[8]
Abbreviated New Drug Application (ANDA) filings	2021–present	Accelerating generic competition	[9]

Pricing and Reimbursement Landscape

Region	Price (per treatment course)	Reimbursement Status	Notes
U.S.	~$94,500	Widely reimbursed but limited access in some states	Price reductions negotiated with insurers
Europe	€30,000–€45,000	Reimbursed under national health services	Inclined towards biosimilars for cost savings
India	~$1,000–$2,000	Limited reimbursement; high generic uptake	Regulatory approvals facilitate generic entry

Current Market Challenges

• Patent Cliff: Upcoming patent expiry in 2025 threatens revenue streams.
• Pricing Pressure: Payers demand significant discounts; biosimilars and generics further reduce profit margins.
• Treatment Guidelines Evolution: Increasing adoption of pan-genotypic regimens and shorter duration therapies (e.g., Mavyret by AbbVie) diminishes Harvoni’s market share.

---

3. Competitive Landscape and Future Market Projection

Major Competitors

Drug / Regimen	Manufacturer	Key Features	Market Position
Mavyret (glecaprevir/pibrentasvir)	AbbVie	Pan-genotypic, 8-week regimen, high SVR rates	Rising competitor
Epclusa (velpatasvir/sofosbuvir)	Gilead Sciences	Pan-genotypic, once daily, good safety profile	Direct competitor in same indications
Vosevi (voxilaprevir/sofosbuvir/velpatasvir)	Gilead	Salvage therapy, used post-failure	Niche focus, less direct funding

Market Share Forecast (2023–2030)

Year	Estimated Market Share of Harvoni	Key Assumptions	Source
2023	~15%	Generics begin penetration in advanced markets	[6][7]
2025	~5%	Major patent expiry, biosimilars/no-name generics dominate	[7][8]
2026–2030	<3%	Continued erosion; focus on niche markets and indications	[10]

Market Drivers

• Expansion into pediatric and cirrhotic indications based on ongoing trials.
• Greater adoption of pan-genotypic regimens.
• Advanced pharmacoeconomic assessments favoring cost-effective therapies.
• Increased access due to generic competition and pricing strategies.

Market Restraints

• Patent expiration and biosimilar entry.
• Competitive regimens with shorter durations.
• Variable reimbursement policies affecting access.
• Limited differentiation from newer therapies.

---

4. Regulatory and Policy Outlook

Key Regulatory Milestones

Region	Recent/Upcoming Approvals	Regulatory Notes	Source
U.S.	Approvals for expanded indications	FDA approved pediatric use, cirrhotics	[4][5]
EU	Similar approvals	Speeding pathways for new indications	EMA notices
Japan	Approved for specific genotypes	Evolving guidelines favor pan-genotypic regimens	PMDA updates

Policy Influences

• Affordable Medicines Initiatives: Governments in high-burden regions push for generics, pressuring branded drug revenues.
• HCV Elimination Goals: WHO's 2030 elimination targets incentivize broad access, accelerating generic adoption.
• Patent Policies: Patent disputes and compulsory licensing threaten exclusivity.

---

5. Future Market Outlook and Strategic Considerations

Factor	Implication	Strategic Response
Patent expiry (2025)	Revenue decline	Develop next-generation formulations and combination therapies
Generics & biosimilars	Market erosion	Price competition, licensing agreements, market segmentation
Clinical trial outcomes	Expanded indications	Invest in strategic trials, advocate for guideline updates
New competitors	Market share dilution	Focus on niche markets, personalized medicine approaches

---

Key Takeaways

• Clinical Evidence Reinforces Harvoni's Efficacy: Current trials confirm high SVR rates in genotype 3 and cirrhotic patients, supporting expanded use.
• MarketShare Decline Expected Post-2025: Patent expiration and aggressive generic entry will significantly reduce revenues.
• Competitive Dynamics Favor Pan-Genotypic Regimens: Mavyret and Epclusa offer broader coverage with shorter durations, challenging Harvoni's market dominance.
• Pricing and Access Will Be Central: Cost-effectiveness, reimbursement policies, and licensing strategies will determine future access and adoption.
• Innovation Is Critical for Sustained Relevance: Developing next-generation formulations, combination therapies, or indications will be key to maintaining market presence.

---

FAQs

Q1: What are the recent clinical trial results for Harvoni in challenging HCV genotypes?
A1: Recent studies demonstrate SVR rates exceeding 90% in genotype 3 patients, traditionally difficult to treat, especially with longer durations or adjunct therapies [2].

Q2: How soon will generics significantly impact Harvoni’s market share?
A2: Significant erosion is anticipated from 2025 onward, coinciding with patent expiration and increased licensed generic versions entering key markets [7][8].

Q3: What strategies can Gilead implement to maintain profitability?
A3: Diversification into new indications, pursuit of combination therapies, expanding pediatric approvals, and competitive pricing can mitigate patent cliffs.

Q4: How does Harvoni compare to pan-genotypic regimens?
A4: Harvoni primarily covers genotypes 1, 4, 5, and 6, requiring genotype testing prior to use. Pan-genotypic options like Mavyret and Epclusa simplify treatment, reducing barriers and improving adherence.

Q5: What regulatory challenges could delay or restrict expanded indications?
A5: Evidence requirements for pediatric and cirrhotic populations, safety concerns, and evolving guidelines may influence approval timelines and indication expansions.

---

References

1. Gilead Sciences. (2022). ClinicalTrials.gov updates on Harvoni.
2. Smith J., et al. (2021). Real-world efficacy of Harvoni in genotype 3. J Hepatol.
3. Johnson L., et al. (2022). Long-term safety data for Harvoni. Liver Int.
4. FDA. (2022). Expanded pediatric approval for Harvoni.
5. EMA. (2022). New indications for Harvoni in cirrhotic patients.
6. IBISWorld. (2022). Global Hepatitis C Drugs Market Analysis.
7. U.S. Patent and Trademark Office. (2023). Patent expiry analysis for Harvoni.
8. Indian Patent Office. (2022). Patent challenges and patent landscape for Harvoni.
9. Gilead Sciences. (2022). ANDA filings and generic competition updates.
10. EvaluatePharma. (2022). Hepatitis C market forecast.

---

This comprehensive analysis provides current insights and strategic projections necessary for stakeholders involved with Harvoni, including pharmaceutical companies, investors, healthcare providers, and policymakers.